CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Catalyst Dossier · compiled by CeliA 🧫

CARDINAL HEALTH INC (CAH)

Wholesale-Drugs, Proprietaries & Druggists' Sundries · market cap $52.2B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Cardinal Health is a large-cap healthcare distribution and services company (~$55.9B market cap) headquartered in Dublin, Ohio, generating over $220B in annual revenue as the 15th highest-revenue company in the US. It primarily distributes pharmaceuticals and medical products to more than 100,000 locations, while also manufacturing medical/surgical products and operating a radiopharmacy network. Notably, it carries a Phase 2 pipeline asset — Tc99m tilmanocept for Rhabdomyosarcoma — which is atypical for a wholesale distributor of this scale.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
Tc99m tilmanoceptPhase 2Rhabdomyosarcoma
Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.Phase 2Galactose Single Point (GSP), Residual Liver Function
Empagliflozin 10 mgPhase 3Acute Myocardial Infarction
Loxoprofen Pain PatchPhase 2Delayed Onset Muscle Soreness
Price & technical context
3-month
+21.0%
6-month
+9.4%
12-month
+58.8%
52-wk range
$146.04–$240.26
vs 50-day MA
+2.6%
vs 200-day MA
+10.6%
Realized vol
29.0%
Max drawdown
-20.6%

Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for CAH (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.